COMMUNIQUÉS West-GlobeNewswire

Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
07/10/2026
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia [...]
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
07/10/2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that [...]
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
07/10/2026
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira [...]
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
07/10/2026
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no [...]
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
07/10/2026
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech [...]
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
07/10/2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS Phase [...]
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
07/10/2026
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in [...]
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference
07/10/2026
Updated preclinical data and clinical trial-in-progress poster from the Harmony-HHT Phase 1/2 trial support the ongoing development of ATV-1601, an investigational oral allosteric inhibitor that selectively targets AKT1 [...]
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
07/10/2026
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
07/10/2026
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE [...]
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
07/10/2026
Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005 Cadrenal has received strong interest from potential strategic partners Cadrenal will [...]
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
07/10/2026
Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN [...]
SparkLabs Taiwan Announces Professor Shan-Qun Huang’s Planned Return to Taiwan to Support International Capital Cooperation and Financial Talent Development
07/10/2026
TAIPEI, Taiwan, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Following the completion of a recent phase of overseas investment research projects, Professor Shan-Chun Huang is planning to gradually shift the focus of his next stage [...]
New study finds a majority of younger men spend an unhealthy amount of time on social media, significantly impacting their mental health
07/10/2026
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Latest research shows more than half of young Canadian men spend over 3 hours a day on social media which significantly increases their risk of poor mental [...]
Une nouvelle étude révèle qu’une majorité de jeunes hommes passent un temps excessif sur les médias sociaux, ce qui peut avoir des répercussions importantes sur leur santé mentale
07/10/2026
VANCOUVER, Colombie-Britannique, 07 oct. 2026 (GLOBE NEWSWIRE) -- Une recherche récente révèle que plus de la moitié des jeunes hommes canadiens passent plus de trois heures par jour sur les médias sociaux, ce qui [...]
Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery
07/10/2026
New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader [...]
ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026
07/10/2026
Data will be presented in two top-rated oral presentations Meet the Expert session offers insights into Actinium-225 production Garching / Munich, October 7 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading [...]
MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence
07/10/2026
Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE- [...]
Dubai Sets the Stage for the Future of Healthcare with Next Generation Medicine 2026
07/10/2026
DUBAI, United Arab Emirates, Oct. 07, 2026 (GLOBE NEWSWIRE) -- As Dubai rapidly solidifies its position as a global epicentre for preventive care, healthcare innovation, and health span extension, the Next Generation [...]

Pages